Related Experiment Video
Updated: Jul 10, 2026
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Cyclophosphamide Plus Rituximab Versus Cyclophosphamide in Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Jiahui Wang1,2,3, Xin Lei1,2,3, Junni Wang1,2,3
1Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Rationale & Objective:
Intravenous cyclophosphamide (CTX) or rituximab (RTX) combined with glucocorticoids are first-line therapies for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). We aimed to compare the efficacy of CTX plus RTX and CTX alone, in combination with glucocorticoids, for AAV patients with kidney injury.
Study Design:
Retrospective cohort study.
Setting & Participants:
76 newly diagnosed AAV patients with kidney involvement, divided into glucocorticoids plus CTX group (control group, n = 36) and glucocorticoids plus CTX and RTX group (combination group, n = 40).
Exposure:
CTX plus RTX or CTX alone, in combination with glucocorticoids.
Outcomes:
Kidney failure, remission, death, combined events endpoint of kidney failure and/or death, relapse, and adverse events.
Analytical Approach:
Unpaired t test, Mann-Whitney U test, Pearson χ2 test or Fisher exact test, and Kaplan-Meier method with log-rank test.
Results:
The median follow-up period was 29.7 (20.4-37.4) months. The remission rate was significantly higher in the combination group than in the control group at 6 months (85.0% vs 52.8%, P = 0.002). However, there were no significant differences in the remission rates at 12 months and at the final follow-up, as well as kidney failure, death, relapse, or improvement of renal function during follow-up between groups. The cumulative dose of glucocorticoids in the combination group was 2.5 (2.0-3.3) g at 6 months and 3.7 (2.6-4.8) g at the final follow-up, significantly lower than those in the control group (P < 0.001 and P < 0.001, respectively). In the subgroup of 45 patients with an estimated glomerular filtration rate of >15 mL/min/1.73 m2 at admission, 7 of 21 patients in the control group and 1 of 24 patients in the combination group progressed to kidney failure (33.3% vs 4.2%, P = 0.02).
Limitations:
Primarily Chinese, retrospective data.
Conclusions:
The combination of glucocorticoids, CTX, and RTX is better in achieving early disease remission and reducing the dose of glucocorticoids for AAV patients.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention